1. Spain Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Naturhouse Health SA

Naturhouse Health SA

2.24
EUR
+0.05
(+2.28%)
Feb 26Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1
1.6
1.6
1.63
1.58
1.46
1.36
0.92
0.96
0.87
0.84
0.82
0.79
- -
Basic EPS, GAAP
0.14
0.38
0.38
0.38
0.33
0.26
0.22
0.16
0.22
0.16
0.19
0.16
0.17
- -
Free Cash Flow per Basic Share
0.12
0.36
0.33
0.25
0.24
0.32
0.33
0.24
0.27
0.1
0.34
0.19
0.19
- -
Dividend per Share
0.12
0.43
0.26
0.28
0.38
0.34
0.25
- -
0.06
0.3
0.1
0.2
0.3
- -
Book Value per Share
0.2
0.25
0.36
0.45
0.41
0.31
0.27
0.43
0.6
0.46
0.51
0.53
0.3
0.51
Tangible Book Value per Share
0.19
0.21
0.33
0.42
0.38
0.29
0.25
0.42
0.59
0.45
0.5
0.52
0.29
0.5
Basic Weighted Avg Shares
60
60
60
60
60
60
60
60
60
60
60
60
60
60
Sales/Revenue/Turnover
60
96
96
98
95
87
82
55
58
52
50
49
48
- -
Operating Margin (%)
21.1
33.93
34.09
32.33
29.77
25.27
22.89
26.09
30.46
24.51
32.29
26.58
27.8
- -
Depreciation Expense
1
1
1
1
1
1
4
3
2
2
2
2
1
- -
Net Income, GAAP
9
23
23
23
20
15
13
9
13
10
11
10
10
- -
Effective Tax Rate (%)
35.04
31.72
31.31
29.97
30.74
32.41
31.35
30.54
26.74
26.59
27.04
27.17
26.29
- -
Profit Margin (%)
14.27
23.57
23.86
23.01
20.97
17.61
16.23
17.03
23.2
18.37
22.4
19.96
21.19
- -
Working Capital
11
9
15
21
18
13
10
24
29
19
22
22
8
28
LT Debt
6
2
- -
- -
- -
- -
5
2
1
2
2
2
2
2
Total Equity
13
15
22
27
25
19
17
26
36
28
31
32
18
31
Return on Invested Capital (%)
- -
74.42
86.82
79.48
71.39
65.97
59.04
33.11
36.2
26.03
34.45
26.94
34.83
- -
Return on Capital (%)
- -
84.18
100.9
88.15
76.94
71.16
62.65
35.23
39.48
28.19
36.32
29.08
37
- -
Return on Common Equity (%)
- -
167.43
123.32
91.92
76.98
70.99
75.14
44.22
43.11
30.16
38.65
31.66
40.84
- -

Capital Structure

EUR

•

in mil. unless spec.
Sep'20
Dec'20
Jun'21
ST Debt
- -
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
60
60
60
Market Capitalization
- -
- -
- -

Working Capital

EUR

•

in mil. unless spec.
Sep'20
Dec'20
Jun'21
Total Current Assets
33
33
43
Cash, Cash Equivalents & STI
22
22
32
Accounts Receivable, Net
4
4
4
Inventories
3
3
3
Total Current Liabilities
11
10
15
Payables & Accruals
- -
- -
- -
ST Debt
- -
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.1%
-2.95%
-43.96%
Free Cash Flow
12.1%
28.31%
4.04%
Net Income, GAAP
-5.74%
4.3%
2.34%
Sales/Revenue/Turnover
-6.17%
-2.77%
-3.63%
Total Cash Common Dividend
- -
- -
50%

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
50
2024
- -
- -
49
2025
- -
- -
48

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.19
2024
- -
- -
0.16
2025
- -
- -
0.17

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.1
2024
- -
- -
0.2
2025
- -
- -
0.3

Company Description

Company Profile APIChatGPT
CEO
Félix Revuelta Fernández
Full Time Employees
163
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Street Claudio Coello 91 Madrid Spain 28006
IPO Date
May 22, 2015
Website
naturhouse.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Naturhouse Health, S.A. operates primarily in the nutrition and dietetics industry, focusing on weight loss and weight management through its proprietary "Naturhouse Method." The company offers a comprehensive range of products including food supplements made from natural extracts designed to facilitate nutrient consumption; diet foods and drinks for breakfast, snacks, and meal substitutes allowing calorie intake control; and cosmetics and body care products targeted at skincare during slimming processes such as cellulite treatment and firming, as well as anti-aging products. The company also markets herbal remedies and natural cosmetics. Naturhouse conducts its production, preparation, and marketing activities mainly through a network of directly operated stores and franchised centers located primarily in Spain, Italy, France, Poland, and other international markets. Founded in 1992 and headquartered in La Rioja, Spain, Naturhouse is a vertically integrated group with subsidiaries that engage in similar activities under the Naturhouse brand. Recent major changes include Naturhouse Health's strategic focus on reinforcing its franchise model while continuing to expand its footprint in Europe and other international markets. The company reported solid financial performance in the first half of 2025 with net income growth and ongoing operational improvements despite broader economic uncertainties. Naturhouse continues developing its product portfolio and service offerings with an emphasis on personalized dietetic advice supported by qualified specialists, enhancing its core "Naturhouse Method." There is no recent indication of large-scale acquisitions or name changes, but the company places significant emphasis on innovation in dietary and cosmetic product lines and on digital tools to improve customer engagement and monitoring. These developments underscore Naturhouse's commitment to maintaining its leadership in the European dietetics sector and expanding its presence globally while sustaining profitability through cost control and franchise expansion. Overall, Naturhouse Health, S.A. is a consumer defensive sector company specializing in packaged foods and dietary products, operating through a vertically integrated business model centered on weight control and healthy eating with a strong brand presence in the European market and beyond. Its business strategy is supported by nutrition expertise, franchise network expansion, and diversified product lines in the dietetics, food supplements, and cosmetics segments. The company reported revenues of approximately €48 million and a net income above €10 million in 2025, reinforcing its stable market positioning and strategic growth trajectory.